日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors

综合 CRISPR 筛选和药物分析可确定 EGFR、ALK 和 BRAF/MEK 抑制剂的联合用药机会

Ralph Tiedt, Frederick J King, Christelle Stamm, Matthew J Niederst, Scott Delach, Sabine Zumstein-Mecker, Jodi Meltzer, Iain J Mulford, Emma Labrot, Barbara Schacher Engstler, Sabrina Baltschukat, Grainne Kerr, Javad Golji, Daniel Wyss, Christian Schnell, Edward Ainscow, Jeffrey A Engelman, William

LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors

LXH254 是一种强效且选择性的 BRAF 和 CRAF 抑制剂,用于治疗 MAPK 驱动的肿瘤

Kelli-Ann Monaco, Scott Delach, Jing Yuan, Yuji Mishina, Paul Fordjour, Emma Labrot, Daniel McKay, Ribo Guo, Stacy Higgins, Hui Qin Wang, Jinsheng Liang, Karen Bui, John Green, Peter Aspesi, Jessi Ambrose, Felipa Mapa, Lesley Griner, Mariela Jaskelioff, John Fuller, Kenneth Crawford, Gwynn Pardee, S

Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling

与变构 SHP2 抑制剂 TNO155 联合使用以阻断受体酪氨酸激酶信号传导

Chen Liu #, Hengyu Lu #, Hongyun Wang, Alice Loo, Xiamei Zhang, Guizhi Yang, Colleen Kowal, Scott Delach, Ye Wang, Silvia Goldoni, William D Hastings, Karrie Wong, Hui Gao, Matthew J Meyer, Susan E Moody, Matthew J LaMarche, Jeffrey A Engelman, Juliet A Williams, Peter S Hammerman, Tinya J Abrams, M

Correction: The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models

更正:强效且选择性的细胞周期蛋白依赖性激酶 4 和 6 抑制剂 ribociclib (LEE011) 是临床前癌症模型中用途广泛的联合用药伙伴。

Kim, Sunkyu; Tiedt, Ralph; Loo, Alice; Horn, Thomas; Delach, Scott; Kovats, Steven; Haas, Kristy; Engstler, Barbara Schacher; Cao, Alexander; Pinzon-Ortiz, Maria; Mulford, Iain; Acker, Michael G; Chopra, Rajiv; Brain, Christopher; Tomaso, Emmanuelle di; Sellers, William R; Caponigro, Giordano

The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models

强效且选择性的细胞周期蛋白依赖性激酶 4 和 6 抑制剂 ribociclib (LEE011) 是临床前癌症模型中用途广泛的联合用药伙伴。

Kim, Sunkyu; Tiedt, Ralph; Loo, Alice; Horn, Thomas; Delach, Scott; Kovats, Steven; Haas, Kristy; Engstler, Barbara Schacher; Cao, Alexander; Pinzon-Ortiz, Maria; Mulford, Iain; Acker, Michael G; Chopra, Rajiv; Brain, Christopher; di Tomaso, Emmanuelle; Sellers, William R; Caponigro, Giordano

Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma

MEK1/2 和 CDK4/6 抑制对神经母细胞瘤的临床前治疗协同作用

Lori S Hart, JulieAnn Rader, Pichai Raman, Vandana Batra, Mike R Russell, Matthew Tsang, Maria Gagliardi, Lucy Chen, Daniel Martinez, Yimei Li, Andrew Wood, Sunkyu Kim, Sudha Parasuraman, Scott Delach, Kristina A Cole, Shiva Krupa, Markus Boehm, Malte Peters, Giordano Caponigro, John M Maris

Whole genome amplification of DNA from laser capture-microdissected tissue for high-throughput single nucleotide polymorphism and short tandem repeat genotyping

对来自激光捕获显微切割组织的 DNA 进行全基因组扩增,用于高通量单核苷酸多态性和短串联重复基因分型

Martha S Rook, Scott M Delach, Galina Deyneko, Andrew Worlock, Jia Liu Wolfe